Barry Gumbiner1, Brooke Esteves2,3, Vanessa Dell4, Tenshang Joh5, Pamela D Garzone6, Alison Forgie5, Chandrasekhar Udata5. 1. Pfizer Inc., 10777 Science Center Dr, San Diego, CA, 92121, USA. barry.gumbiner@pfizer.com. 2. Pfizer Inc., 7 Shipley Circle, Westford, MA, 01886, USA. 3. ImmunoGen, Inc., 830 Winter Street, Waltham, MA, 02451, USA. 4. Pfizer Inc. Maine, 235 E. 42nd Street, New York, NY, 10017, USA. 5. Pfizer Inc., 10646 Science Center Drive, La Jolla, CA, 92121, USA. 6. Pfizer Inc., 230 East Grand Ave, South San Francisco, CA, 94080, USA.
Abstract
PURPOSE: This first-in-human study assessed safety, immunogenicity, pharmacokinetics, and pharmacodynamics of RN909, a monoclonal antibody antagonist of the glucagon receptor, in type 2 diabetes (T2DM) subjects. METHODS: This study enrolled 84 T2DM subjects receiving stable metformin regimens. Forty-four subjects were randomized to receive single escalating doses of RN909 (0.3 to 6 mg/kg subcutaneously (SC), or 1 mg/kg intravenously (IV)), or placebo; 40 subjects were randomized to receive multiple escalating doses (50 to 150 mg SC) or placebo every 4 weeks for 12 weeks. RESULTS:RN909 was well tolerated; treatment-related elevated liver function tests (LFTs) were observed in 4/33 (12.1%) and 5/32 (15.6%) subjects treated with single and multiple doses, respectively, versus 1/10 (10%) and 0 in the respective placebo groups. RN909 dose-normalized AUCinf increased more than dose-proportionally following single SC doses, and after multiple doses, accumulation ratios ranged from 1.3 to 3.4. The incidence of antidrug antibodies (ADA) was 33% after single doses and 50% after multiple doses. RN909 produced dose-dependent, durable fasting plasma glucose (FPG)-lowering at day 29 (mean change -20.6 to -97.5 mg/dL) and day 85 (mean change; -27.2 to -43.5 mg/dL) after single and multiple doses, respectively. HbA1c also was reduced after single (mean change -0.30% to -1.44%), and multiple doses (-0.83% to -1.56%). CONCLUSION:RN909 was well tolerated after single and multiple doses in T2DM subjects, with diarrhea and elevated LFTs the most frequent adverse events. The appearance of ADA did not affect pharmacokinetics or efficacy. Robust lowering of FPG and HbA1c was observed.
RCT Entities:
PURPOSE: This first-in-human study assessed safety, immunogenicity, pharmacokinetics, and pharmacodynamics of RN909, a monoclonal antibody antagonist of the glucagon receptor, in type 2 diabetes (T2DM) subjects. METHODS: This study enrolled 84 T2DM subjects receiving stable metformin regimens. Forty-four subjects were randomized to receive single escalating doses of RN909 (0.3 to 6 mg/kg subcutaneously (SC), or 1 mg/kg intravenously (IV)), or placebo; 40 subjects were randomized to receive multiple escalating doses (50 to 150 mg SC) or placebo every 4 weeks for 12 weeks. RESULTS:RN909 was well tolerated; treatment-related elevated liver function tests (LFTs) were observed in 4/33 (12.1%) and 5/32 (15.6%) subjects treated with single and multiple doses, respectively, versus 1/10 (10%) and 0 in the respective placebo groups. RN909 dose-normalized AUCinf increased more than dose-proportionally following single SC doses, and after multiple doses, accumulation ratios ranged from 1.3 to 3.4. The incidence of antidrug antibodies (ADA) was 33% after single doses and 50% after multiple doses. RN909 produced dose-dependent, durable fasting plasma glucose (FPG)-lowering at day 29 (mean change -20.6 to -97.5 mg/dL) and day 85 (mean change; -27.2 to -43.5 mg/dL) after single and multiple doses, respectively. HbA1c also was reduced after single (mean change -0.30% to -1.44%), and multiple doses (-0.83% to -1.56%). CONCLUSION:RN909 was well tolerated after single and multiple doses in T2DM subjects, with diarrhea and elevated LFTs the most frequent adverse events. The appearance of ADA did not affect pharmacokinetics or efficacy. Robust lowering of FPG and HbA1c was observed.
Entities:
Keywords:
Glucagon; Glucose; RN909; Safety; Type 2 diabetes mellitus
Authors: Kenneth T Luu; Erin S Morgan; Sanjay Bhanot; Richard Geary; Anne Smith; Claudette Bethune; Lynnetta Watts; Scott Henry; Yanfeng Wang Journal: J Pharmacokinet Pharmacodyn Date: 2017-01-28 Impact factor: 2.745
Authors: Christof M Kazda; Ying Ding; Ronan P Kelly; Parag Garhyan; Chunxue Shi; Chay Ngee Lim; Haoda Fu; David E Watson; Andrew J Lewin; William H Landschulz; Mark A Deeg; David E Moller; Thomas A Hardy Journal: Diabetes Care Date: 2015-12-17 Impact factor: 17.152
Authors: Hong-Ping Guan; Xiaodong Yang; Ku Lu; Sheng-Ping Wang; Jose M Castro-Perez; Stephen Previs; Michael Wright; Vinit Shah; Kithsiri Herath; Dan Xie; Daphne Szeto; Gail Forrest; Jing Chen Xiao; Oksana Palyha; Li-Ping Sun; Paula J Andryuk; Samuel S Engel; Yusheng Xiong; Songnian Lin; David E Kelley; Mark D Erion; Harry R Davis; Liangsu Wang Journal: J Lipid Res Date: 2015-09-15 Impact factor: 6.676
Authors: R P Kelly; P Garhyan; E Raddad; H Fu; C N Lim; M J Prince; J A Pinaire; M T Loh; M A Deeg Journal: Diabetes Obes Metab Date: 2015-03-02 Impact factor: 6.408
Authors: Ana Kostic; Thomas Alexander King; Feng Yang; Kuo-Chen Chan; George D Yancopoulos; Jesper Gromada; Joyce B Harp Journal: Diabetes Obes Metab Date: 2017-09-14 Impact factor: 6.577
Authors: Eric G Vajda; Douglas Logan; Kenneth Lasseter; Danielle Armas; Diane J Plotkin; J D Pipkin; Yong-Xi Li; Rong Zhou; David Klein; Xiaoxiong Wei; Stacy Dilzer; Lin Zhi; Keith B Marschke Journal: Diabetes Obes Metab Date: 2016-08-31 Impact factor: 6.577